Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 2/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.45 |
| ▸ | GLB1 | P16278 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26504295 | 0.93 | GNAI3 (0.53) | GNAI3GNAO1GNAI1USP2SIGMAR1 | |
| SCHEMBL23841915 | 0.91 | GNAI3 (0.52) | GNAI3GNAO1GNAI1GLB1SIGMAR1 | |
| SCHEMBL20384645 | 0.91 | GNAI3 (0.41) | GNAI3GNAO1GNAI1USP2GBA1 | |
| SCHEMBL13519627 | 0.91 | GNAI3 (0.45) | GNAI3GNAO1GNAI1GLB1USP2 | |
| SCHEMBL20445417 | 0.91 | GNAI3 (0.45) | GNAI3GNAO1GNAI1GLB1USP2 | |
| SCHEMBL25565620 | 0.91 | GBA1 (0.46) | GNAI3GNAO1GNAI1GBA1TP53 | |
| SCHEMBL11932497 | 0.86 | GBA1 (0.41) | GNAI3GNAO1GNAI1GBA1TP53 | |
| SCHEMBL27057345 | 0.86 | GBA1 (0.43) | GNAI3GNAO1GNAI1GBA1TP53 | |
| SCHEMBL25123284 | 0.86 | GBA1 (0.43) | GBA1TP53SMN1; SMN2 | |
| SCHEMBL19861164 | 0.84 | GNAI3 (0.44) | GNAI3GNAO1GNAI1USP2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MEDICI THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MEDICI THERAPEUTICS, INC. | 2023-09-21 | — | — | US | disclosed |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | NUTCRACKER THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | NUTCRACKER THERAPEUTICS, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| WO-2022087335-A1 | KRAS PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| US-8562966-B2 | End-modified poly(beta-amino esters) and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2013-10-22 | — | — | US | disclosed |
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-06-14 | — | — | US | disclosed |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149630-A1 | END-MODIFIED POLY(BETA-AMINO ESTERS) AND USES THEREOF | PARN, PARG, POLL | GNAI3 2281/4885GNAO1 3609/4885GNAI1 2437/4885 |
| US-20230293706-A1 | Multicomponent Delivery Systems for Polyanionic Cargo Compound Delivery | MTREX, EXOSC5, KPNA6 | GNAI3 2855/4885GNAO1 4205/4885GNAI1 2940/4885 |
| US-20080242626-A1 | End-Modified Poly(beta-amino esters) and Uses Thereof | PARN, PARG, POLL | GNAI3 2281/4885GNAO1 3609/4885GNAI1 2437/4885 |
| US-11701434-B2 | Tertiary amino lipidated cationic peptides for nucleic acid delivery | LNPEP, SLC7A1, APLNR | GNAI3 3437/4885GNAO1 4542/4885GNAI1 3705/4885 |
| US-20240025863-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | GNAI3 1953/4885GNAO1 894/4885GNAI1 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.